Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer

Title:Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer

Volume: 24

Author(s): Xia Li, Weiwei Chen, Shu Jiang, Lianlian Zhang, Hua Huang, Yanan Ji, Qinggan Ni*Chunhua Ling*

Affiliation:

• Department of Burns and Plastic Surgery, Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng, Yancheng, 224000, PR China

• Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, PR China

Abstract:

Background: Sodium voltage-gated channel beta subunit 4 (SCN4B) plays a suppressive role in various tumors. However, the role of SCN4B in non-small cell lung cancer (NSCLC) is not yet clear. This study aims to investigate the expression of SCN4B in NSCLC patients and its correlation with prognosis.

Methods: Firstly, the expression of SCN4B in non-small cell lung cancer (NSCLC) was analyzed using The Cancer Genome Atlas (TCGA) database. Then, differential expression genes (DEGs) were identified using R software. Next, DEG enrichment pathways were analyzed using the R package clusterProfiler. Protein-protein interaction networks were revealed through STRING analysis. A heatmap showed significant differential expression of SCN4B. Further analysis included examining SCN4B expression in a pan-cancer context and its correlation with 24 types of immune cells in NSCLC. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), Western Blot, immunohistochemistry, and clinical data were used to validate SCN4B expression and prognostic value in NSCLC patients.

Results: SCN4B mRNA expression in non-small cell lung cancer tissues was significantly lower than in adjacent normal tissues (p < 0.001). Clinical correlation analysis confirmed its association with clinical pathology. Gene set enrichment analysis (GSEA) and tumor immune-related analyses indicated that SCN4B is involved in NSCLC-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and participates in immune infiltration. qRT-PCR, Western Blot, and immunohistochemistry also confirmed that SCN4B is downregulated in NSCLC patients and is associated with poor prognosis.

Conclusion: SCN4B is downregulated in tumor tissues of NSCLC patients and is associated with a poor prognosis.

Cite this article as:

Li Xia, Chen Weiwei, Jiang Shu, Zhang Lianlian, Huang Hua, Ji Yanan, Ni Qinggan*, Ling Chunhua*, Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer, Current Cancer Drug Targets 2024; 24 () . https://dx.doi.org/10.2174/0115680096293516240607071915